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Primary effusion lymphoma (PEL)
without effusion: a patient case
report of a PEL solid variant
Primary effusion lymphoma (PEL) is a very
rare type of lymphoma that is usually
confined to the body cavities such as the
pleural space, pericardium and peritoneum.
PEL is associated with human herpes virus-8
(HHV-8) infection and commonly observed
in HIV-infected patients.
We present a case of PEL confirmed by
pathology without effusion in a 38-year-old
man at initial HIV diagnosis.
A 38-year-old man presented with a right
axillary swelling, restricted arm movement
and chest pain for 3 weeks. He reported
weight loss of 4 kg and night sweat without
fever and/or chills. On physical examination,
we found enlarged neck and axillary lymph
nodes with a diameter of 3 cm, movable and
hard presentation without tenderness.
Elevation of the right shoulder was restricted
to 208 with intact circulation and sensitivity.
Lab reports showed a haemoglobin value
of 7.8 g/dl, albumin 3.4 g/dl, lactate dehy-
drogenase 255 U/l and creatinine 1.6 mg/dl.
Total serum protein was elevated to 10.3 g/dl
and the fraction of g globulins was expanded
to 44% without monoclonal globulin. In
a 24-hour urine collection test, mild
proteinuria (0.52 g/24 h) with k and l light
chain elevation (278 and 80.2 mg/l, respec-
tively) was present, while immunofixation
electrophoresis of the serum was negative.
MR and CT scans of the right shoulder
showed enlarged axillary lymph nodes with
3 cm diameter infiltrating medullary space of
the caput and corpus humeri without
destructing the corticalis (figure 1A). In the
CT scan, mild enlarged lymph nodes in
cervical, inguinal and iliac sites (1.5e3.3 cm)
as well as an enlarged spleen 1434.5312 cm
were found.
Lymph node extirpation of the right axil-
lary bulk could be performed and gross path-
ological examination showed a conglomerate
with two discernable grey-coloured nodules.
First, the lymph nodes showed the histo-
pathology of acute to subacute HIV lymph-
adenitis with lymphofollicular hyperplasia
with reactive hyperplastic germinal centres
and extensive accumulation of plasma cells
(CD20+, CD79a+, MUM1+, p24-antigen+,
EBV+). Second, a predominantly intra-
sinusoidal (subcapsular and medullary) infil-
tration was seen, which might represent
a very early infiltration of the lymph node,
by large blastic cells with large nuclei and
prominent nucleoli (figure 2A). In immuno-
histochemical studies, these blastic cells
strongly expressed CD30, CD138, MUM 1
and HHV-8 and were found negative for
CD20, CD45, CD79a, PAX 5, CD56 and
ALK. Immunoglobulin light chain k and l
showed polyclonal expression. Additionally,
an EpsteineBarr virus-encoded RNA in situ
hybridisation was strongly positive (figure
2BeD). After consulting the Reference
Center for Lymph Node Pathology (Univer-
sity of Wuerzburg), a PEL was diagnosed.
HIV and hepatitis serology revealed
a positive HIV-1 immunoblot and RT-PCR
with 19 000 copies/ml. The CD4 cell count
was 390/ml.
Due to unique clinical presentation of PEL
with lymphomatous growth and without
tumour cells in effusions, the patient
underwent cardiac and abdominal ultra-
sound imaging; however, the pericardial,
pleural and peritoneal spaces were
completely free of effusions.
Antiretroviral therapy with nevirapine,
lamivudine and abacavir was initiated, but
the patient experienced significant progres-
sive disease with tumour growth at all sites
and with ongoing destruction of the
humerus.
Chemotherapy with cyclophosphamide,
doxorubicin, vincristine and prednisone
(CHOP) was administered, and after three
cycles, staging CT scans showed partial
remission. Moreover, creatinine and lactate
dehydrogenase showed normal results
(0.9 mg/dl and 196 U/l) and haemoglobin
increased to 13.3 g/dl. After another three
cycles, the patient achieved complete
remission in staging CT scan (figure 1B).
Figure 3 (A) In common with the ovarian
follicle granulosa cells, the adjacent cell
clusters stain strongly positive with a-inhibin.
(B) The cells fail to stain with the epithelial
marker CAM 5.2.
Figure 1 CT imaging of the right shoulder at initial diagnosis (A) and after six cycles of
chemotherapy/HAART (B). (A) Right shoulder with axillary lymph nodes infiltrating caput and
corpus humeri. (B) Normal finding of the right shoulder and axillary lymph nodes.
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PEL was first described in 1989. Since
then, its unique pathogenesis, the role of
HHV-8 and EBV infection have been eluci-
dated.1 Currently, only very few longitudinal
observational series of patients with PEL
have defined optimal treatment strategies.2
PEL solid variants (without effusion) are
very rare with only a few cases reported in
literature. A retrospective series of four cases
with solid variants have been reported by
Carbone et al Despite treatment with CHOP
chemotherapy and highly active anti-
retroviral therapy (HAART), all patients died
of disease progression within 15e55 days.3
As described by Simonelli and Boulanger
et al, the absence of HAART before PEL
diagnosis is the strongest predictor of poor
clinical outcome in the population of HIV-
infected patients with PEL.4 5 This may be
related to the reversion of severe immuno-
deficiency by HAART and therefore
enhanced tolerance to chemotherapy
toxicity and reduction of treatment-related
mortality. Control of HIV replication and
immunological recovery could also slow PEL
progression.5 As reported by Carbone et al,
Kaposi’s sarcoma-associated herpesvirus/
HHV-8 (KSHV)-positive solid lymphomas
show a PEL-specific profile in the gene
expression levels.3 Patients who develop PEL
may be more immunosuppressed than
patients with the KSHV-positive solid
variant.6 In a small series of KSHV-positive
solid lymphomas, eight patients with solid
variant PEL had a slightly better survival rate
compared with 21 cases with PEL.6
Two major laboratory abnormalities,
anaemia and hypoalbuminaemia, have been
described in PEL solid variant individuals.3
This is a very rare description of a solid
variant of PEL without effusion, both at
initial diagnosis and in the later course of the
disease. The case also accentuates the
necessity of molecular testing for HHV-8
even in the absence of the ‘classical clinical
features’ in high-risk patients. CHOP with or
without granulocyte colony-stimulating
factor support may be a candidate for safe
and effective treatment in these patients.
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Benign phyllodes tumour with
intraductal papillary growth of the
breast in a young woman
A 24-year-old woman noted a mass in her left
breast and visited a local hospital. The mass
was w2.5 cm in size upon imaging and
considered to be a benign tumour, so she was
monitored. Six months later, the mass
enlarged to >3 cm, showed redness in the
skin and was painful. She took antibiotics for
1 week, and symptoms improved. She was
referred to the Social Insurance Kurume
Daiichi Hospital (Kurume, Japan). Ultraso-
nography revealed an intracystic tumour
measuring w3.333.333.5 cm consisting of
a solid papillary structure in a cystic lesion
and with an inhomogeneous interior (figure
1). DynamicMRI revealed an irregular-shaped
solid portion, with enhancement within the
Figure 2 Histology and immunohistochemistry. (A) Lymph follicle on the right, atypical cells left
in between (HE, 1003/4003). (B) Negativity for CD20 (CD20, 4003). (C) Positivity for HHV-8
(HHV-8, 4003). (D) Positivity for CD30 (CD30, 4003).
Key messages
< Primary effusion lymphoma (PEL) is
rarely found in immunocompromised
patients.
< HHV-8 immunohistochemical testing
should be applied even in absence of
‘classical clinical features’.
< Highly active anti-retroviral therapy
(HAART) in combination with CHOP
regimen chemotherapy is a feasible
option for patients with PEL solid
variant.
190 J Clin Pathol February 2012 Vol 65 No 2
PostScript
group.bmj.com on November 20, 2014 - Published by http://jcp.bmj.com/Downloaded from 
variant
effusion: a patient case report of a PEL solid 
Primary effusion lymphoma (PEL) without
Bogner and Helmut Ostermann
Rosenwald, Roswitha Forstpointner, Volker Heinemann, Johannes R
Graser, Hans Roland Duerr, Doris Mayr, Thomas Kirchner, Andreas 
Clemens Giessen, Dorit Di Gioia, Bruno Huber, Bettina Seppi, Anno
doi: 10.1136/jclinpath-2011-200279
2011
2012 65: 189-190 originally published online October 19,J Clin Pathol 
 http://jcp.bmj.com/content/65/2/189




This article cites 6 articles, 3 of which you can access for free at: 
service
Email alerting
box at the top right corner of the online article. 
Receive free email alerts when new articles cite this article. Sign up in the
Notes
http://group.bmj.com/group/rights-licensing/permissions
To request permissions go to:
http://journals.bmj.com/cgi/reprintform
To order reprints go to:
http://group.bmj.com/subscribe/
To subscribe to BMJ go to:
group.bmj.com on November 20, 2014 - Published by http://jcp.bmj.com/Downloaded from 
